AbCellera IPO Presentation Deck
December 2020, 38 slides
  1. AbCellera
  2. Related Decks
  3. IPO Presentation Decks
business peel years carl chief executive officer femur booth | AbCellera
disclaimers we ere cee be ree nee a a are necessarily subject to a of uncertainty and risk revised to information becomes of afar inn gate me me a discover and deliver to our partners strategic plans partnerships the met tae we have registration statement on form preliminary with the securities and a be see a has not yet become effective our common shares may not be sold nor may offers buy be accepted to a ices cee reel dee me doer tee a a and thew acceptance by mow and cunning partners our our ability to attention louts north united states of expand out current or ender into new our dependence in recent kas dah i he ere cee a sea a tee barking avenue of the finer by at new york a ale ere a pee a at all our ability compete in the and platform technology market our to protect ree get a lake eta on a a dee a bes ear | AbCellera
offering summary issuer ticker base offering size a option to purchase additional shares price range gross proceeds million as of cain i i use to use of proceeds lock up period expected pricing date the efforts pita soc and | AbCellera
technology is the mae we believe the new frontier of technology lies at the triple digit profitable positive centralized business model for antibody based therapeutics market full stack powered antibody discovery engine ley to founded in so discovered covid antibody authorized for me us canada | AbCellera
cro drug development fails too often mele seme a ted to years of rate ory drug development average antibody forester tech access impact drug developers focus on getting one result is drug candidate to the finish line the a chronic in the technologies to make the process of drug development better | AbCellera
a a new technologies and a new business model are needed to lead antibody discovery and capture the antibody based coe i poise teel | AbCellera
the opportunity access the of natural antibodies cro the immune system is a that encodes nature answers for fighting diseases and infections but it been challenging to access the billions of unique antibodies inside each is made by a single cell lately antibody finding each patient the cell that makes it powered by over antibodies created by natural immune systems benefit from selection quality assurance and optimization of approved antibody drugs are derived from natural immune systems | AbCellera
the solution a unique combination of a a i a a i immune response any optimized immunization from any species single cell screening to search immune cells single cell repertoire profiling sera crate art high throughput of select chains candidate a a eld a singe am | AbCellera
the tech stack an powered platform built on real world data deep tech complex integration at scale many life sciences companies have technologies that focus on one or a limited number of steps in the process we believe we uniquely integrate proprietary technologies hat address each of these steps eas gid pst he a i tic bier i mauler alloy lie joe rats i are peer tis me ase examples of companies with technologies at different steps of our technology stack include | AbCellera
the business strategy cro democratize the industry technology advantage antibody discovery operating system | AbCellera
kit gat sizes undisclosed partners large cap pharmaceutical and companies of all | AbCellera
case study covid authorized for emergency use in the canada i injection watt risk reduction in hospitalizations sue | AbCellera
ust help everyone share in the success partner clinical phase phase pee tell building a diversified portfolio of milestones royalties primary value driver discovery research fees milestones near term revenue from research rill multimillion dollar potential clinical and commercial milestone payments majority of risk adjusted value from royalty on commercial therapeutic | AbCellera
historical performance key performance indicators participating in the success mel malaise of discovery partners cumulative of programs under contract cumulative of program starts with downstream participation without downstream participation without downstream participation pis a so a wear name end | AbCellera
cro historical performance milestones triple digit profitable positive a tule seme yard as rite rie par closed secured first lay cried milestones awarded be eat closed series a opened poses patents for antibodies say a platform approved funding for government of canada project am elm alloy acquired platform acquired mouse | AbCellera
or our founder led team of employees includes engineers and data scientists scientists and business professionals i moody carl pho bee a aes peter a mes chairman beet operating officer belts i eels eld difficult targets ped ped finance eer pega ice me bes head of research group leader cell berets senior manager scientific director git he tad be operating officer me | AbCellera
carl chief executive officer femur booth | AbCellera
technology stack | AbCellera
source | AbCellera
source immunization optimization control immunity to dot we aim to generate and access a high quality libel ace a immunization methods a a belt from rodents we trigger immune generating the best responses from any antibodies with the species with the goal of most diversity | AbCellera
search | AbCellera
a antibody response with single cell assays a a sil bee ava bee antibodies antigen costed beads a mel integrating chambers per setup to screen millions of cells each ceil is tested for the secretion of mim positive binding is detected by high throughput fluorescence microscopy and processed using | AbCellera
search for any antibody property search high throughput single cell screening bah a fra | AbCellera
find | AbCellera
find single cell repertoire profiling cro a seat a pea bat an a single cell lead through sequence mapping a on of it con a tae | AbCellera
analyze | AbCellera
eas sires wee protocols allows thousands of samples high throughput with optimized industrialized cloning expression per week | AbCellera
ora ase a dimensional data cloud for each antibody cro high throughput binding expression a earth i tee validation a tie a a i analytics a generate virtual data clouds around each antibody to assess function and biophysical properties needed for rapid drug development tae poe affinity | AbCellera
analyze antibody visualization ere compile compute and visualize big data custom built data collection across entire pipeline partnership model feeds unique dimensional computation based on computational structure and data analytics front end interface connects scientists to data through interactive visualization light chain | AbCellera
engineer | AbCellera
cro source bien engineer protein engineering stot ers bam moot our protein engineering tool kit supports next generation antibody therapeutics such as constructs humanization optimization and most recently antibodies that enable the following therapeutic modalities tara bait a at peat protein scaffolding | AbCellera
a elle ors veer engineering technology develop with native like format diverse panels stable manufacturable proven platform optimized discovery yields standardized mad seme i cee as engineering options predictable development antibody format | AbCellera
cro tae seme protein protein interfaces with to mutations per stable pairing of multiple heavy and light chains example mutations at interface my pia i a a | AbCellera
intellectual property | AbCellera
intellectual property or global intellectual property portfolio with foundational patents applications owned or exclusively licensed patent families tit immune rep sie foundational claims on high throughput single cell secretion assays with application to antibody discovery clone selection via elt | AbCellera
expansion | AbCellera
expansion research development cro expand the breadth depth so amine my integrate full manufacturing a i we new ion channel and protein coupled receptors technology for antigen design and immunization ere its development manufacturing facility for production of for clinical testing | AbCellera
expansion manufacturing the goal future plans for deepening the tech stack include a a a financial post receives million from the government of canada to discover solutions for covid and build a manufacturing facility for antibody drugs cell line development manufacturing facility for production of for clinical testing this facility which is partly funded by a grant by the government of canada will be the first in canada capable of going from a patient sample to manufacturing antibodies for clinical testing | AbCellera
See More
AbCellera
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Manufacturing
Downstream
Antibody discovery
Drug development
Recent decks by AbCellera
Investor Presentation
February 2024
Investor Conference
January 2024
Results
November 2023
Investor Presentation
November 2023
See all presentations by AbCellera (23 decks)
Related decks
Berkeley Lights
Investor Conference
January 2021
BenevolentAI
Investor Presentation
September 2024
Taysha
IPO
September 2020
GreenLight
SPAC
August 2021
Fusion Pharmaceuticals
Investor Presentation
January 2024
Enochian Biosciences
Investor Presentation
January 2024
Bluejay
IPO
October 2021
OmniAb
Investor Presentation
August 2023
Recent decks by AbCellera
See all presentations (23 decks)
Investor Presentation
February 2024
Investor Conference
January 2024
Results
November 2023
Investor Presentation
November 2023
Berkeley Lights
Investor Conference
January 2021
BenevolentAI
Investor Presentation
September 2024
Taysha
IPO
September 2020
GreenLight
SPAC
August 2021
Fusion Pharmaceuticals
Investor Presentation
January 2024
Enochian Biosciences
Investor Presentation
January 2024
Bluejay
IPO
October 2021
OmniAb
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights